09:00 AM EDT, 10/25/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that its skin treatment, Tremfya, has achieved statistical significance across all primary endpoints in a phase 3b study.

The company said the study showed that treatment with Tremfya resulted in clear or almost clear skin in most patients with low body surface area moderate plaque psoriasis with special site involvement who failed topical treatment.

The company said the drug also showed statistically significant improvements across all major secondary endpoints.

Price: 163.66, Change: -0.01, Percent Change: -0.01